Lupin completes acquisition of VISUfarma, expands European ophthalmology portfolio
News by Aliceblue News Desk
02 Apr 2026
Introduction
Leading global pharmaceutical firm completes acquisition of VISUfarma B.V., expanding its European ophthalmology portfolio to over 60 products and strengthening presence across key European markets.
Also Read: Bharat Electronics bags fresh ₹6,795 crore orders, stock price moves up 6%
Share price movement of Lupin
On April 02, 2026, Lupin Ltd opened at ₹2,271.95, down 0.09% from its previous close of ₹2,273.60. The stock reached a high of ₹2,271.95 and a low of ₹2,171.95. By 12:33 PM, it traded at ₹2,255.55, a 0.79% decrease, with a market cap of ₹1,03,119.03 crore.
Lupin Acquires VISUfarma B.V.
Lupin Limited has completed the acquisition of VISUfarma B.V. from GHO Capital Partners. The acquisition expands Lupin’s European specialty pharmaceutical portfolio in ophthalmology.
VISUfarma adds over 60 branded eye care products. The company operates in Italy, UK, Spain, Germany, and France, strengthening Lupin’s specialty care presence and expertise in ophthalmology.
Stock performance of Lupin for period of 1 week, 6 months, and 1 year
Lupin Ltd delivered a 1-week return of -3.10%, a 6-month return of 15.3%, and a 1-year return of 13.2%.
Also Read: Steel Strips Wheels hits record ₹500 Cr sales, truck segment drives surge; share price rallies 13%
Shareholding pattern of Lupin
| Particulars | Dec 2025 | Sep 2025 | Jun 2025 |
| Promoter | 46.90% | 47% | 46.90% |
| FII | 22% | 21% | 21% |
| DII | 25.60% | 26.60% | 25.60% |
| Public | 6% | 6% | 6.30% |
About Lupin
Lupin Limited (NSE: LUPIN) is a global pharmaceutical company with products in over 100 markets, specializing in generics, biotechnology, APIs, and multiple therapy areas.
Stay Ahead with the Latest Stock Market Updates – Click Here
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
FAQs
Q: Why is Lupin Limited share price in focus today?
A: Lupin Limited is in focus after firm completes VISUfarma B.V acquisition, expanding European ophthalmology portfolio to over 60 products and strengthening presence in key markets.
Q: What is Lupin Limited’s main business focus?
A: Lupin Limited focuses on pharmaceuticals, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.
Q: What are the 52-week high and low of Lupin Limited stock?
A: Lupin Limited stock has a 52-week high of ₹2,376.00 and a 52-week low of ₹1,774.00.
News Author
Aliceblue News Desk
